EVESTIA CLINICAL LIMITED

• ◆

  1 PSC ceased in last 24 months

  Significant control changed hands — see the Ownership section.

1. EVESTIA CLINICAL LIMITED 2025-04-08 → present
2. EMAS PHARMA LIMITED 2012-11-21 → 2025-04-08
3. EUROPEAN MEDICAL ADVISORY SERVICES LIMITED 1996-05-03 → 2012-11-21
4. IN FRONT LIMITED 1996-04-17 → 1996-05-03

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

FRS 102

Reporting scope

Consolidated group

Auditor

RSM UK Audit LLP

Audit opinion

Unqualified (clean)

Going concern

Affirmed

“The financial statements have been prepared on the going concern basis which the directors believe to be appropriate for the following reasons. The directors have prepared cash flow forecasts for a 12 month period from the date of approval of these financial statements and such forecasts have indicated that sufficient funds should be available to enable the Company to continue in operational existence for the foreseeable future by meeting its liabilities as they fall due for payment. The directors have assessed the going concern assumption at a Group and Company level. The Group has received a letter of support from the majority shareholder that states that they remain supportive of the Group's growth strategy and that further financial support can be provided to ensure that the Group is able to meet its financial commitments for at least the 12 month period from the date of approval of these financial statements. In addition, the company has received a support letter from its immediate parent company, confirming support and that the intra group creditor will not be recalled until the Company has sufficient cash to repay it.”

Group structure

1. EVESTIA CLINICAL LIMITED · parent
   1. Evestia Clinical Inc 100% · Virginia, United States · Healthcare related services
   2. Evestia Pharma Pty Ltd 100% · Australia · Healthcare related services

Significant events

• “On 7th December Kester Capital III LP (a fund managed by Kester Capital LLP) alongside the management team, acquired Evestia Clinical Limited and its subsidiaries, via the immediate parent company Project Barcelona Bidco Limited.”
• “Effective 8 April 2025, the Company changed its name from EMAS Pharma Limited to Evestia Clinical Limited.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

7

last 12 months

Capital events

1

last 24 months

Officers appointed

0

last 12 months

Officers resigned

0

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  -31.5%

  £10,720,000 → £7,347,000

• Cash

  +2,453.2%

  £111,000 → £2,834,000

• Net assets

  +203.6%

  -£1,121,000 → £1,161,000

• Employees

  -8.3%

  72 → 66

• Operating profit

  -1,083.8%

  £327,000 → -£3,217,000

• Profit before tax

  -176,550%

  £2,000 → -£3,529,000

• Wages

  +16.4%

  £4,796,000 → £5,584,000

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers